Duopharma reaches settlement in drug trademark dispute with Sun Pharma

Traders Union
All News
Business & Wealth
Companies
Duopharma resolves Sun Pharma dispute

Highlights

Sun Pharma withdraws trademark lawsuit against Duopharma at the Kuala Lumpur High Court, resulting in the trial scheduled for this Monday being vacated.
The settlement terms between Duopharma and Sun Pharma were not disclosed, removing litigation risk but leaving the direct financial impact uncertain.
Duopharma shares closed one sen lower, or 0.91%, at RM1.09 on Monday, with a market capitalisation of RM1.05 billion.

This article was translated from the original. Read the original version by our correspondent here.

Settlement details and court proceedings

As reported by The Edge Malaysia, Duopharma said in a stock exchange filing that Sun Pharma had filed a notice of discontinuance at the Kuala Lumpur High Court without leave to refile and with no order as to costs. Following the filing, the court vacated the trial that was due to begin on Monday.

However, Duopharma did not disclose the terms of the settlement with Sun Pharma. In February 2025, the group announced that Sun Pharma had filed a lawsuit against its wholly owned unit, Duopharma Manufacturing (Bangi) Sdn Bhd, in the Kuala Lumpur court.

According to Duopharma, both trademarks are used on tablet medicines intended to lower cholesterol levels and reduce the risk of heart disease. Sun Pharma alleged that Duopharma's drug name, "Crystorvas", infringed its registered trademark, "Storvas", creating public confusion and the impression that the product was associated with Sun Pharma.

Implications for the company and market operations

In its lawsuit, Sun Pharma sought an injunction against the use of the Crystorvas mark, a recall of the product from the market and destruction of the medicine, an order to cancel the trademark, and an inquiry into damages. Before the current settlement was reached, Duopharma maintained that the registration and use of the Crystorvas trademark were lawful and pledged to vigorously defend the case.

Duopharma shares closed one sen lower, or 0.91%, at RM1.09 on Monday, giving it a market capitalisation of RM1.05 billion. The settlement removes a litigation risk for the pharmaceutical group, although the commercial details and any direct financial impact of the agreement were not disclosed.

In our earlier report on Mycron Steel Bhd withdrawing its judicial review over the abolition of anti-dumping duties, the company discontinued its legal challenge following discussions described as constructive and stressed that the move was not driven by a court decision. The withdrawal closed off a key legal avenue against the import policy change, shifting the focus to the commercial impact and price competition in the domestic steel market.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.